Article Text

Download PDFPDF

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients
  1. Melisa Martinez-Paniagua1,
  2. Cara Haymaker2,
  3. Jay R Adolacion3,
  4. Laszlo Radvanyi4,
  5. Patrick Hwu2,
  6. Badrinath Roysam1,
  7. Chantale Bernatchez2 and
  8. Navin Varadarajan1
  1. Aff1 grid.266436.30000000415699707University of Houston Houston TX USA
  2. Aff2 grid.240145.60000000122914776UT MD Anderson Cancer Center Houston TX USA
  3. Aff3 grid.266436.30000 0004 1569 9707University of HoustonUniversity of the Philippines Houston TX USA
  4. Aff4 grid.468198.a0000 0000 9891 5233Moffit Cancer Center Tampa FL USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Adoptive cell therapy (ACT) of tumor infiltrating lymphocytes (TIL) has shown the ability to induce complete regression of stage IV melanoma. Two challenges associated TIL ACT are that (i) T cells are capable of different anti-tumor effector functions including cytotoxicity, cytokine secretion, and homing to target tissues, and currently no methodologies exist that can inform on all of these functions for a given (single) cell, and (ii) the relative contributions of each of these effector functions to the overall anti-tumor effect remains un-quantified.


Here, we evaluated a set of four infusion products from patients treated with TIL ACT: two Complete Responders (CR) and two patients with Progressive Disease (PD) with high percentages of CD8+ T cell population and with established autologous primary tumor cell lines.


Flow cytometry analysis of the tumor reactive TIL showed no difference in the frequency of TIL secreting IFN-γ or degranulating in response to the autologous tumor. Utilizing Timelapse Imaging Microscopy In Nanowell Grids (TIMING), we demonstrate that while the frequencies of individual TIL participating in killing of autologous tumor cells is equivalent across the donors, TIL from CR patients demonstrated a longer duration of conjugation prior to killing the tumor cell (CR 211 ± 7 min vs PD 131 ± 5 min). Furthermore, both in the presence and absence of tumors cells, the motility of the TIL was significantly higher (CR 4.7 ± 0.2 µm vs PD 2.9 ± 0.1 µm). Multiplexed single-cell gene-expression profiling of the TIL, classified based on activated functional states (CD69/CD107a/IFN-γ) demonstrated that the functional classification was not useful in clustering cells from different donors but rather, clustering of cells was dictated by the donor regardless of function. Lastly, we demonstrate that a core signature of the activated TIL consisting of CD37, CD44, IL7R, CD28, CD27, IFNGR1, TIM-3, MAPK1 and MTOR were up-regulated in CR patients and the levels of TGFB1, BCL2, IL2RG, PDRM1 and IL12RB2 were up-regulated in PD patients.


In summary, our results demonstrate that single cell profiling may be useful in determining not only the transcriptional signatures of TIL with favorable clinical responses but also uncover simple physical attributes like basal motility that might serve as a surrogate marker for activated/functional TIL.